ArticleChemistry & biodiversity2025
Antitumor and Cytogenotoxic Activities of Libidibia ferrea Hydroalcoholic Extracts in Murine Breast Carcinoma.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antitumor and Cytogenotoxic Activities of Libidibia ferrea Hydroalcoholic Extracts in Murine Breast Carcinoma.Chemistry & biodiversity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Breast cancer is the most prevalent cancer type among women worldwide, and there is a critical need for more effective and safer treatments, especially for aggressive and therapy-resistant subtypes. Libidibia ferrea, a native plant from Brazil, exhibits anti-inflammatory, antimicrobial, antioxidant, and antitumor properties. This study evaluated the antioxidant activity and antitumor effects of hydroalcoholic extracts from the leaves (HAFL) and fruits (HAFR) of L. ferrea in murine breast carcinoma models. Chemical analysis revealed several phenolic compounds, including gallic and ellagic acids. HAFR showed three times more total phenolic content than HAFL and exhibited higher antioxidant, cytotoxic, and genotoxic activities, inducing DNA damage and cell death in MDA-MB-231 cells. In a 4T1 murine model, HAFR reduced tumor growth by 94% at doses of 0.3 and 3.0 g/kg without affecting body or liver weight. These findings suggest HAFR's potential as a therapeutic candidate for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.